blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2942392

EP2942392 - DIFFERENTIATION OF PLURIPOTENT STEM CELLS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.08.2019
Database last updated on 14.03.2026
FormerThe patent has been granted
Status updated on  31.08.2018
FormerGrant of patent is intended
Status updated on  05.04.2018
FormerExamination is in progress
Status updated on  02.11.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Janssen Biotech, Inc.
800/850 Ridgeview Drive
Horsham, PA 19044 / US
[2015/46]
Inventor(s)01 / LIU, Jiajian
J&J Consumer Companies
199 Grandview Road
Skillman, NJ 08558 / US
02 / DAVIS, Janet
J&J Consumer Companies
199 Grandview Road
Skillman, NJ 08558 / US
03 / PARMENTER, Christine
3210 Merryfield Row
San Diego, CA 92121 / US
04 / BONNET, Pascal Ghislain André
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
 [2018/40]
Former [2015/46]01 / LIU, Jiajian
J&J Consumer Companies
199 Grandview Road
Skillman, NJ New Jersey 08558 / US
02 / DAVIS, Janet
J&J Consumer Companies
199 Grandview Road
Skillman, NJ New Jersey 08558 / US
03 / PARMENTER, Christine
3210 Merryfield Row
San Diego, CA California 92121 / US
04 / BONNET, Pascal Ghislain André
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse / BE
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2015/46]
Application number, filing date15171064.730.06.2009
[2015/46]
Priority number, dateUS20080076908P30.06.2008         Original published format: US 76908 P
US20080076900P30.06.2008         Original published format: US 76900 P
US20080076915P30.06.2008         Original published format: US 76915 P
[2015/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2942392
Date:11.11.2015
Language:EN
[2015/46]
Type: B1 Patent specification 
No.:EP2942392
Date:03.10.2018
Language:EN
[2018/40]
Search report(s)(Supplementary) European search report - dispatched on:EP29.09.2015
ClassificationIPC:C12N5/0735, C12N5/071
[2015/46]
CPC:
C12N5/0606 (EP,KR,US); C12N5/0018 (KR,RU); C07K14/475 (KR);
C12N5/00 (KR,RU); C12N5/0676 (EP,US); C12N5/0678 (US);
C12N5/0696 (KR); C12N2500/25 (EP,US); C12N2501/11 (EP,US);
C12N2501/115 (EP,US); C12N2501/119 (EP,US); C12N2501/135 (EP,US);
C12N2501/15 (EP,US); C12N2501/155 (EP,US); C12N2501/16 (EP,US);
C12N2501/165 (EP,US); C12N2501/19 (EP,US); C12N2501/385 (EP,US);
C12N2501/41 (EP,US); C12N2501/415 (EP,US); C12N2501/42 (EP,US);
C12N2501/727 (EP,US); C12N2501/845 (EP,US); C12N2501/999 (EP,US);
C12N2506/02 (EP,US); C12N2531/00 (EP,US); C12N2533/50 (EP,US);
C12N2533/90 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/25]
Former [2015/46]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:DIFFERENZIERUNG PLURIPOTENTER STAMMZELLEN[2015/46]
English:DIFFERENTIATION OF PLURIPOTENT STEM CELLS[2015/46]
French:DIFFÉRENCIATION DE CELLULES SOUCHES PLURIPOTENTES[2015/46]
Examination procedure11.05.2016Amendment by applicant (claims and/or description)
11.05.2016Examination requested  [2016/25]
22.06.2016Despatch of a communication from the examining division (Time limit: M06)
30.12.2016Reply to a communication from the examining division
29.09.2017Despatch of a communication from the examining division (Time limit: M04)
08.02.2018Reply to a communication from the examining division
05.04.2018Communication of intention to grant the patent
15.08.2018Fee for grant paid
15.08.2018Fee for publishing/printing paid
15.08.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP09774297.7  / EP2310492
Opposition(s)04.07.2019No opposition filed within time limit [2019/37]
Fees paidRenewal fee
08.06.2015Renewal fee patent year 03
08.06.2015Renewal fee patent year 04
08.06.2015Renewal fee patent year 05
08.06.2015Renewal fee patent year 06
08.06.2015Renewal fee patent year 07
10.06.2016Renewal fee patent year 08
16.06.2017Renewal fee patent year 09
12.06.2018Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.06.2009
AT03.10.2018
CY03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
MK03.10.2018
MT03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
BE30.06.2019
CH30.06.2019
IE30.06.2019
LI30.06.2019
LU30.06.2019
PL30.06.2019
[2022/31]
Former [2021/34]HU30.06.2009
AT03.10.2018
CY03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
MT03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
BE30.06.2019
CH30.06.2019
IE30.06.2019
LI30.06.2019
LU30.06.2019
PL30.06.2019
Former [2021/32]HU30.06.2009
AT03.10.2018
CY03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
BE30.06.2019
CH30.06.2019
IE30.06.2019
LI30.06.2019
LU30.06.2019
PL30.06.2019
Former [2021/26]AT03.10.2018
CY03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
BE30.06.2019
CH30.06.2019
IE30.06.2019
LI30.06.2019
LU30.06.2019
PL30.06.2019
Former [2020/51]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
BE30.06.2019
CH30.06.2019
IE30.06.2019
LI30.06.2019
LU30.06.2019
PL30.06.2019
Former [2020/25]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
BE30.06.2019
CH30.06.2019
IE30.06.2019
LI30.06.2019
LU30.06.2019
Former [2020/21]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
IE30.06.2019
Former [2020/17]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2020/08]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/50]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/40]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
SK03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/37]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
RO03.10.2018
SE03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/34]AT03.10.2018
CZ03.10.2018
DK03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
SE03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/26]AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
SE03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/24]AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
SE03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
Former [2019/23]AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
BG03.01.2019
NO03.01.2019
IS03.02.2019
Former [2019/22]CZ03.10.2018
FI03.10.2018
LT03.10.2018
NL03.10.2018
BG03.01.2019
NO03.01.2019
IS03.02.2019
Former [2019/21]FI03.10.2018
LT03.10.2018
NL03.10.2018
NO03.01.2019
IS03.02.2019
Former [2019/20]LT03.10.2018
NL03.10.2018
NO03.01.2019
Former [2019/17]NL03.10.2018
Documents cited:Search[A] WO2008048647  (CYTHERA INC et al.)
 [A]   MCLEAN AMANDA B ET AL: "Activin a efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, vol. 25, no. 1, 1 January 2007 (2007-01-01), pages 29 - 38, XP002482637, ISSN: 1066-5099

DOI:   http://dx.doi.org/10.1634/stemcells.2006-0219
 [A]   ARMSTRONG LYLE ET AL: "The role of PI3K/AKT, MAPK/ERK and NF kappa beta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, vol. 15, no. 11, 1 June 2006 (2006-06-01), pages 1894 - 1913, XP002471543, ISSN: 0964-6906

DOI:   http://dx.doi.org/10.1093/hmg/ddl112
 [A]   PALING N R D ET AL: "REGULATION OF EMBRYONIC STEM CELL SELF-RENEWAL BY PHOSPHOINOSITIDE 3-KINASE-DEPENDENT SIGNALING", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 279, no. 46, 24 August 2004 (2004-08-24), pages 48063 - 48070, XP002380573, ISSN: 0021-9258

DOI:   http://dx.doi.org/10.1074/jbc.M406467200
 [AD]   HORI YUICHI ET AL: "Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 25, 10 December 2002 (2002-12-10), pages 16105 - 16110, XP002392968, ISSN: 0027-8424

DOI:   http://dx.doi.org/10.1073/pnas.252618999
 [A]   MCKIERNAN EADAOIN ET AL: "Directed differentiation of mouse embryonic stem cells into pancreatic-like or neuronal- and glial-like phenotypes.", TISSUE ENGINEERING OCT 2007, vol. 13, no. 10, October 2007 (2007-10-01), pages 2419 - 2430, XP002547893, ISSN: 1076-3279

DOI:   http://dx.doi.org/10.1089/ten.2006.0373
 [A]   SHIRAKI NOBUAKI ET AL: "Guided differentiation of embryonic stem cells into Pdx1-expressing regional-specific definitive endoderm.", STEM CELLS (DAYTON, OHIO) APR 2008, vol. 26, no. 4, April 2008 (2008-04-01), pages 874 - 885, XP002547894, ISSN: 1549-4918

DOI:   http://dx.doi.org/10.1634/stemcells.2007-0608
 [A]   KUBO A ET AL: "Development of definitive endoderm from embryonic stem cells in culture", DEVELOPMENT, COMPANY OF BIOLOGISTS, CAMBRIDGE, GB, vol. 131, no. 7, 1 April 2004 (2004-04-01), pages 1651 - 1662, XP002985523, ISSN: 0950-1991

DOI:   http://dx.doi.org/10.1242/dev.01044
by applicantUS2006003446
 US6200806
 WO9920741
 WO0151616
 US2005266554
 US2006040387
 US5843780
 WO2007003525
 US73690807
 US77931107
 US99052907
 US95317807
 US2004209901
 US2004132729
 US5770417
 US6022743
 US5567612
 US5759830
 US6626950
 US6534084
 US6306424
 US6365149
 US6599323
 US6656488
 US2004062753
 US4557264
 US6333029
 US6509369
 US6793945
 US6331298
 US2004220393
 US2004171623
 US11644708
   LUMELSKY ET AL., SCIENCE, vol. 292, 2001, pages 1389
   SORIA ET AL., DIABETES, vol. 49, 2000, pages 157
   HORI ET AL., PNAS, vol. 99, 2002, pages 16105
   BLYSZCZUK ET AL., PNAS, vol. 100, 2003, pages 998
   DIABETES, vol. 54, 2005, pages 301
   DIABETES, vol. 53, 2004, pages 1030
   BIOCHEM.J., vol. 379, 2004, pages 749
   GENES CELLS, vol. 10, no. 6, June 2005 (2005-06-01), pages 503 - 16
   GORDON ET AL., PNAS, vol. 103, 2006, pages 16806
   SCIENCE, vol. 282, 1998, pages 114
   SHAMBLOTT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 13726
   D'AMOUR ET AL., NATURE BIOTECHNOLOGY, vol. 24, 2006, pages 1392 - 1401
   BENVENISTRY; BENVENISTRY ET AL.: "We conclude that over-expression of PDX1 enhanced expression of pancreatic enriched genes, induction of insulin expression may require additional signals that are only present in vivo", STEM CELLS, vol. 24, 2006, pages 1923 - 1930
   PANGAS, S.A.; WOODRUFF, T.K: "Isolation of inhibin and activin from natural sources can only produce limited quantities ofbioactive protein.", J. ENDOCRINOL., vol. 172, 2002, pages 199 - 210
   ARAI, K. Y. ET AL.: "Isolation of activins from natural sources requires many steps and only produces limited quantities. Even though recombinant preparations have been used in recent studies, purification of recombinant activins still requires multiple steps.", PROTEIN EXPRESSION AND PURIFICATION, vol. 49, 2006, pages 78 - 82
   SCIENCE, vol. 282, 1998, pages 1145
   CURR. TOP. DEV. BIOL., vol. 38, 1998, pages 133 FF
   PROC. NATL. ACAD. SCI. U.S.A., vol. 92, 1995, pages 7844
   TAKAHASHI ET AL., CELL, vol. 131, 2007, pages 1 - 12
   KLEINMAN, H.K. ET AL., BIOCHEMISTRY, vol. 25, 1986, pages 312
   HADLEY, M.A. ET AL., J.CELL.BIOL., vol. 101, 1985, pages 1511
   "Current Protocols in Molecular Biology", 2001
   HARLOW; LANE: "Using Antibodies: A Laboratory Manual", 1998, COLD SPRING HARBOR LABORATORY PRESS
   D'AMOUR ET AL., NATURE BIOTECHNOLOGY, vol. 24, 2006, pages 1392 - 1401
   NATURE BIOTECHNOLOGY, vol. 24, 2006, pages 1392 - 1401
   D' AMOUR ET AL., NATURE BIOTECHNOLOGY, 2006
   EDLUND, NATURE REVIEWS GENETICS, vol. 3, 2002, pages 524 - 632
   J. PEDIATR. SURG., vol. 23, 1988, pages 3 - 9
   BIOTECHNOL. PROG., vol. 14, no. 2, 1998, pages 193 - 202
   J. BIOMED. MATER. RES., vol. 55, no. 3, 2001, pages 379 - 86
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.